-
€31.5 million raised
-
Market capitalisation of €128.4 million
-
6th listing of a biotech on Euronext Paris in 2021
-
175th listing on Euronext in 2021
Paris – 08 November 2021 – Euronext today congratulates MaaT Pharma, a company specialized in the research and development of microbiota biotherapies, on its listing on the regulated market of Euronext Paris (ticker code: MAAT).
Founded in 2014 and based in Lyon, MaaT Pharma is developing an innovative therapeutic approach focused on oncology through modulation of the gut microbiota. MaaT Pharma's methodology is based on its MET ("Microbiome Ecosystem Therapy") platform for the design of prospective drugs with high microbial diversity from healthy donors or produced by co-fermentation. The company is currently developing three prospective drugs, the most advanced of which is ready to enter Phase 3 clinical trials, to improve the chances of survival of patients with acute graft-versus-host disease. The IPO aims to strengthen MaaT Pharma’s development in the field of microbiota modulation in oncology, to progressively broaden its product portfolio by developing new innovative microbiota-based therapies and to build an integrated biopharmaceutical company.
MaaT Pharma was listed through the admission to trading on 8 November 2021 of the 9,514,780 shares making up its equity and of 2,333,333 new shares issued under a Global Offering[1], before the potential exercise of the over-allotment option.
The admission and issue price of MaaT Pharma shares was set at €13.5 per share. Market capitalisation was €128.4 million on the day of listing. The Initial Public Offering (IPO) raised €31.5 million altogether.
Hervé Affagard, co-founder and CEO of MaaT Pharma, said: “This IPO opens a new chapter in the history of MaaT Pharma and represents an important milestone for our sector, as it is the first listing of a company developing microbiota-based drugs in continental Europe. Our entire team would like to thank our new shareholders, both institutional and individual, as well as our historical shareholders and our ecosystem, who have chosen to contribute to our success, and whose trust honours us. The funds raised will enable us to pursue our clinical and industrial development plan and to accompany our product MaaT013 into Phase III and then towards a marketing authorisation procedure. Our ambition is to become the reference player in the world of microbiota in oncology for the benefit of millions of patients.”
Caption: Hervé Affagard, co-founder and CEO of MaaT Pharma, rang the bell during a ceremony this morning, alongside Joël Doré, co-founder, and their associates Siân Crouzet, Savita Bernal, Isabelle Adeline, John Weinberg, Carole Schwintner and in the presence of Guillaume Morelli, Director Listing SME France at Euronext, to celebrate the IPO of the company.
About MaaT Pharma MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
[1] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.